Johnson & Johnson (JNJ)

JNJ (NYSE:Drugs)
$100.14
pos +0.00
+0.00%
Today's Range: 100.09 - 102.00 | JNJ Avg Daily Volume: 8,092,000
Last Update: 01/30/15 - 4:02 PM EST
Volume: 0
YTD Performance: -4.24%
Open: $0.00
Previous Close: $102.38
52 Week Range: $86.09 - $109.49
Oustanding Shares: 2,799,110,362
Market Cap: 286,572,918,862
6-Month Chart
TheStreet Ratings Grade for JNJ
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 5 5 5
Moderate Buy 3 3 3 3
Hold 7 7 7 8
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.13 2.13 2.13 2.19
Latest Dividend: 0.70
Latest Dividend Yield: 2.73%
Dividend Ex-Date: 02/20/15
Price Earnings Ratio: 17.15
Price Earnings Comparisons:
JNJ Sector Avg. S&P 500
17.15 18.00 25.69
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-6.45% 11.89% 52.40%
GROWTH 12 Mo 3 Yr CAGR
Revenue 6.10 0.14 0.05
Net Income 18.00 0.69 0.19
EPS 18.50 0.63 0.17
Earnings for JNJ:
EBITDA 21.12B
Revenue 74.33B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $1.52 $1.73 $6.21 $6.50
Number of Analysts 8 7 12 11
High Estimate $1.60 $1.86 $6.30 $6.61
Low Estimate $1.43 $1.50 $6.15 $6.32
Prior Year $1.54 $1.66 $5.97 $6.21
Growth Rate (Year over Year) -1.06% 4.22% 3.94% 4.83%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Gary Berman

 | Jan 20, 2015 | 10:01 AM EST

I would look to buy the weakness inside the $102.30-$100.59 zone.

By

Chris Versace and Lenore Hawkins

 | Jan 18, 2015 | 5:00 PM EST

Watch the ECB, economic data, and earnings.

bearishJohnson & Johnson downgraded at Goldman

Jan 15, 2015 | 7:07 AM EST

JNJ was downgraded from Neutral to Sell, Goldman Sachs said. $97 price target. Company lacks near-term catalysts. 

By

Christopher Versace

 | Jan 12, 2015 | 9:59 AM EST

Watch the share count when looking at earnings.

By

Jim Cramer

 | Jan 5, 2015 | 10:00 AM EST

The next 10 Dow components in my analysis.

By

Bret Jensen

 | Dec 18, 2014 | 10:00 AM EST

Try these two small biotechs with no connection to the gyrations of energy markets.

By

Bret Jensen

 | Dec 5, 2014 | 11:30 AM EST

Approval of malaria vaccine could provide a shot in the arm.

By

Christopher Versace

 | Oct 25, 2014 | 12:00 PM EDT

Americans are living much longer these days -- and there are a number of ways to invest.

By

Jim Cramer

 | Oct 21, 2014 | 1:28 PM EDT

Welcome back to the airlines and the biotechs.

By

David Katz

 | Oct 21, 2014 | 12:30 PM EDT

Investing during a mid-term election can offer large returns.

It's been a while since I have shown this chart. For the last 2 years the yields on the Fi...
Ugly end to a challenging week as stocks post around three percent declines for the openin...
I have scaled further into a TLT short - scaling all the way up to $138.35 this morning. A...
Market slightly down despite the boost Amazon (AMZN) is giving the NASDAQ. Biotech also co...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.